ReviewJournal of mammary gland biology and neoplasia2012
Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.
Review in Journal of mammary gland biology and neoplasia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Review
- Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects.Cancer medicine · 2022Article
- Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.Oncology letters · 2022Article
- What is known about melatonin, chemotherapy and altered gene expression in breast cancer.Oncology letters · 2017Article
- Role of vascular normalization in benefit from metronomic chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.Cancer cell international · 2017Article
- Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.Archives of medical science : AMS · 2016Article
- Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.Molecular oncology · 2016Article
- Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.Journal of the National Cancer Institute · 2015Article
- A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.Breast cancer research and treatment · 2014Article
- Anandamide inhibits breast tumor-induced angiogenesis.Translational medicine @ UniSa · 2014Article
- Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Angiogenesis · 2014Article
- Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.Japanese journal of clinical oncology · 2014Review
- Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.Investigational new drugs · 2014Article
- Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.JAK-STAT · 2014Article
- Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.Best practice & research. Clinical anaesthesiology · 2013Review
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Breast cancer research : BCR · 2013Review
- The pharmacological bases of the antiangiogenic activity of paclitaxel.Angiogenesis · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viewed as a whole, the aggregate outcomes of a number of positive randomized phase III clinical trial results evaluating the VEGF-pathway targeting antiangiogenic drug bevacizumab, with or without concurrent chemotherapy, in metastatic breast cancer patients have been disappointingly modest. In the case of antiangiogenic tyrosine kinase inhibitors (TKIs) the results have been negative. Nevertheless, several findings indicate antiangiogenic drugs, especially bevacizumab, are active and can lead to demonstrable clinical benefit in some patients, thus stimulating research into developing strategies to significantly improve their efficacy and reduce toxicity. Some of these initiatives include: 1) discovery and validation of predictive markers that can prospectively identify patients more likely to benefit from antiangiogenic therapy; 2) recognition that the nature of the chemotherapy partner or backbone can strongly impact outcomes when combined with antiangiogenic drugs such as bevacizumab, and thus developing what may be improved combination chemotherapy partner regimens, e.g. metronomic chemotherapy; 3) evaluating prospectively in more depth whether subtypes of the disease-especially triple negative or inflammatory breast cancer-are more responsive to antiangiogenic therapy than other subtypes; 4) evaluating new agents that inhibit angiogenesis in a VEGF-independent manner and other types of drug that can be effectively combined with antiangiogenics, e.g. c-met inhibitors; 5) uncovering the basis of resistance or relapse/progression on the therapy with antiangiogenic drugs; 6) development of improved predictive preclinical breast cancer models for therapy testing, e.g. treatment of mice with established multi-organ breast cancer metastatic disease or genetically engineered mouse models of breast cancer, or mice bearing patient derived breast cancer tissue xenografts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.